{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:23:23Z","timestamp":1794353003736,"version":"4.9.0"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"E-Da Dachang Hospital","award":["EDCHP114006"],"award-info":[{"award-number":["EDCHP114006"]}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["BMRPJ30"],"award-info":[{"award-number":["BMRPJ30"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG8P0631"],"award-info":[{"award-number":["CMRPG8P0631"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CORPG8P0561"],"award-info":[{"award-number":["CORPG8P0561"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taiwan National Science and Technology Council","award":["109-2314-B-182A-009-MY2"],"award-info":[{"award-number":["109-2314-B-182A-009-MY2"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Taiwan National Science and Technology Council","award":["111-2314-B-182A-027-"],"award-info":[{"award-number":["111-2314-B-182A-027-"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Taiwan National Science and Technology Council","award":["112-2314-B-182-070-MY3"],"award-info":[{"award-number":["112-2314-B-182-070-MY3"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,7,10]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pharmacological augmentation is commonly used for patients with major depressive disorder (MDD) who respond inadequately to antidepressant treatment. However, the robustness of evidence supporting lithium, second-generation antipsychotics (SGAs), and triiodothyronine (T3) augmentation for MDD remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To reappraise the efficacy and robustness of evidence for pharmacological augmentation strategies for MDD, focusing on lithium, SGAs, and T3. Study selection and analysis: We systematically searched five electronic databases and included placebo-controlled RCTs in adults with MDD who received augmentation with lithium, SGAs, or T3. The primary outcome was response rate (defined as \u226550% depressive symptom reduction). Random-effects meta-analysis and trial sequential analysis (TSA) were conducted. We also performed publication-bias\u2013adjustment analyses, including PET-PEESE and selection models. Subgroup analyses were conducted for individual SGAs.<\/jats:p>\n                    <jats:p>: To reappraise the efficacy and robustness of evidence for pharmacological augmentation strategies for MDD, focusing on lithium, SGAs, and T3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Fifty-six RCTs were included (n=13616). SGA augmentation was associated with a higher response than placebo (k=45; reported as OR with 95% CI: 1.53; 1.42\u20131.65; I\u00b2=0%), and the evidence was supported by TSA. Conversely, while lithium showed benefit in conventional meta-analysis (k=17; OR 2.06; 1.30\u20133.27; I\u00b2=11.5%), this effect was not supported by TSA (accrued information size reached 8% of the required information size; 1.99, TSA-adjusted 95% CI 0.02\u2013189.11) and became statistically non-significant in the PET-PEESE-adjusted and selection models. Additionally, T3 augmentation was not associated with significantly higher response than controls (k = 6; 1.19; 0.53\u20132.70). Among individual SGAs, only aripiprazole, quetiapine, brexpiprazole, and cariprazine demonstrated TSA-supported efficacy, whereas evidence for other SGAs was limited or inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The certainty and robustness of evidence for lithium and T3 augmentation remained limited. Evidence for T3 was sparse and did not show a significant advantage over control, while interpretation of the lithium findings is further constrained by the fact that most trials were conducted before treatment-resistant depression was more operationally defined in contemporary research. SGAs with TSA-supported benefits (aripiprazole, quetiapine, brexpiprazole and cariprazine) may be prioritised, pending individual patient considerations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/osf.io\/27gp9\">https:\/\/osf.io\/27gp9<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2026-302656","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:40:16Z","timestamp":1785411616000},"page":"e302656","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Reappraising lithium, triiodothyronine and second-generation antipsychotic augmentation treatment for major depression: a systematic review and meta-analysis with bias-adjustment analyses"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4136-1251","authenticated-orcid":false,"given":"Tien-Wei","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Psychiatry, E-Da Dachang Hospital, Kaohsiung, Taiwan"},{"name":"Departmnt of Psychiatry, E-Da Hospital, Kaohsiung, Taiwan"},{"name":"School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-4060","authenticated-orcid":false,"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Thompson","sequence":"additional","affiliation":[{"name":"Centre for Chronic Illness and Ageing, University of Greenwich, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre F","family":"Carvalho","sequence":"additional","affiliation":[{"name":"IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Strategic Research Centre, Deakin University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"},{"name":"Comprehensive Centre for Clinical Neurosciences and Mental Health (C3NMH), Medical University of Vienna, Vienna, Austria"},{"name":"Clinical Division of Social Psychiatry, Department of Psychiatry & Psychotherapy, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan"},{"name":"Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tri-Service General Hospital, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology & Preventive Medicine, National Taiwan University, Taipei City, Taiwan"},{"name":"Department of Dentistry, National Taiwan University Hospital, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5586","authenticated-orcid":false,"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Tri-Service General Hospital Beitou Branch, Taipei, Taiwan"},{"name":"Department of Psychiatry, School of Medicine, College of Medicine, National Defense Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2026091806104858000_29.1.e302656.1","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-9-90","article-title":"Cross-national epidemiology of DSM-IV major depressive episode","volume":"9","author":"Bromet","year":"2011","journal-title":"BMC Med"},{"key":"2026091806104858000_29.1.e302656.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.01.060"},{"key":"2026091806104858000_29.1.e302656.3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30925-9"},{"key":"2026091806104858000_29.1.e302656.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.08.036"},{"key":"2026091806104858000_29.1.e302656.5","doi-asserted-by":"publisher","DOI":"10.1002\/da.23135"},{"key":"2026091806104858000_29.1.e302656.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.11.004"},{"key":"2026091806104858000_29.1.e302656.7","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1652053"},{"key":"2026091806104858000_29.1.e302656.8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/104012371202400209","article-title":"Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder","volume":"24","author":"McIntyre","year":"2012","journal-title":"Ann Clin Psychiatry"},{"key":"2026091806104858000_29.1.e302656.9","first-page":"16","article-title":"Augmentation and combination strategies to treat the residual symptoms of major depressive disorder","volume":"4","author":"Fava","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"2026091806104858000_29.1.e302656.10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/13651501.2017.1306082","article-title":"Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines","volume":"21","author":"Bauer","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2026091806104858000_29.1.e302656.11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/07067437241245384","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Reseau canadien pour les traitements de l\u2019humeur et de l\u2019anxiete (CANMAT)","volume":"69","author":"Lam","year":"2023","journal-title":"Can J Psychiatry"},{"key":"2026091806104858000_29.1.e302656.12","doi-asserted-by":"publisher","DOI":"10.1177\/0004867420979353"},{"key":"2026091806104858000_29.1.e302656.13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/02698811211013579","article-title":"Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium","volume":"35","author":"V\u00e1zquez","year":"2021","journal-title":"J Psychopharmacol"},{"key":"2026091806104858000_29.1.e302656.14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/phar.70063","article-title":"Lithium Augmentation in Treatment-Resistant Depression: A Qualitative Review of the Literature","volume":"45","author":"Acero-Gonz\u00e1lez","year":"2025","journal-title":"Pharmacotherapy"},{"key":"2026091806104858000_29.1.e302656.15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S2215-0366(25)00028-8","article-title":"Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK","volume":"12","author":"Cleare","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026091806104858000_29.1.e302656.16","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-7-731","article-title":"Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial","volume":"7","author":"Girlanda","year":"2014","journal-title":"BMC Res Notes"},{"key":"2026091806104858000_29.1.e302656.17","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.1.80"},{"key":"2026091806104858000_29.1.e302656.18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.162.5.634"},{"key":"2026091806104858000_29.1.e302656.19","doi-asserted-by":"crossref","unstructured":"Page MJ , McKenzie J , Bossuyt P . The prisma 2020 statement: an updated guideline for reporting systematic reviews. MetaArXiv [Preprint]. doi:10.31222\/osf.io\/v7gm2_v1","DOI":"10.31222\/osf.io\/v7gm2_v1"},{"key":"2026091806104858000_29.1.e302656.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.05.079"},{"key":"2026091806104858000_29.1.e302656.21","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120"},{"key":"2026091806104858000_29.1.e302656.22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3371\/CSRP.MCCI.010316","article-title":"Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator","volume":"9","author":"McEvoy","year":"2016","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"2026091806104858000_29.1.e302656.23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11538980-000000000-00000","article-title":"Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data","volume":"25","author":"Pae","year":"2011","journal-title":"CNS Drugs"},{"key":"2026091806104858000_29.1.e302656.24","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1176\/appi.ajp.20250292","article-title":"Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial","volume":"182","author":"Durgam","year":"2025","journal-title":"Am J Psychiatry"},{"key":"2026091806104858000_29.1.e302656.25","doi-asserted-by":"publisher","DOI":"10.1002\/da.20130"},{"key":"2026091806104858000_29.1.e302656.26","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0207"},{"key":"2026091806104858000_29.1.e302656.27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/03007995.2018.1430220","article-title":"Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study","volume":"34","author":"Hobart","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2026091806104858000_29.1.e302656.28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1176\/appi.ajp.20220504","article-title":"Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study","volume":"180","author":"Sachs","year":"2023","journal-title":"Am J Psychiatry"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2026-302656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:11:28Z","timestamp":1789737088000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2026-302656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,30]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjment-2026-302656"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2026-302656","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}